Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment.

Bianchi G, Vuerich M, Pellegatti P, Marimpietri D, Emionite L, Marigo I, Bronte V, Di Virgilio F, Pistoia V, Raffaghello L.

Cell Death Dis. 2014 Mar 20;5:e1135. doi: 10.1038/cddis.2014.109.

2.

Tumor-induced CD11b(+) Gr-1(+) myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-dependent manner.

Kapanadze T, Medina-Echeverz J, Gamrekelashvili J, Weiss JM, Wiltrout RH, Kapoor V, Hawk N, Terabe M, Berzofsky JA, Manns MP, Wang E, Marincola FM, Korangy F, Greten TF.

Eur J Immunol. 2015 Apr;45(4):1148-58. doi: 10.1002/eji.201445093. Epub 2015 Feb 23.

3.
4.

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.

Görgün GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J, Raje N, Munshi NC, Richardson PG, Anderson KC.

Blood. 2013 Apr 11;121(15):2975-87. doi: 10.1182/blood-2012-08-448548. Epub 2013 Jan 15.

5.

IL-18 enhances immunosuppressive responses by promoting differentiation into monocytic myeloid-derived suppressor cells.

Lim HX, Hong HJ, Cho D, Kim TS.

J Immunol. 2014 Dec 1;193(11):5453-60. doi: 10.4049/jimmunol.1401282. Epub 2014 Oct 31.

6.

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.

Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P.

Int Immunopharmacol. 2011 Jul;11(7):856-61. doi: 10.1016/j.intimp.2011.01.030. Epub 2011 Feb 11.

7.

Tumor microenvironmental conversion of natural killer cells into myeloid-derived suppressor cells.

Park YJ, Song B, Kim YS, Kim EK, Lee JM, Lee GE, Kim JO, Kim YJ, Chang WS, Kang CY.

Cancer Res. 2013 Sep 15;73(18):5669-81. doi: 10.1158/0008-5472.CAN-13-0545. Epub 2013 Jul 18.

8.

Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.

Hosoi A, Matsushita H, Shimizu K, Fujii S, Ueha S, Abe J, Kurachi M, Maekawa R, Matsushima K, Kakimi K.

Int J Cancer. 2014 Apr 15;134(8):1810-22. doi: 10.1002/ijc.28506. Epub 2013 Oct 21.

9.

Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.

Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, Rizzuto GA, Lazarus JJ, Pamer EG, Houghton AN, Merghoub T, Wolchok JD.

Cancer Res. 2012 Feb 15;72(4):876-86. doi: 10.1158/0008-5472.CAN-11-1792. Epub 2011 Dec 15.

10.
11.

miR-223 suppresses differentiation of tumor-induced CD11b⁺ Gr1⁺ myeloid-derived suppressor cells from bone marrow cells.

Liu Q, Zhang M, Jiang X, Zhang Z, Dai L, Min S, Wu X, He Q, Liu J, Zhang Y, Zhang Z, Yang R.

Int J Cancer. 2011 Dec 1;129(11):2662-73. doi: 10.1002/ijc.25921. Epub 2011 Mar 25.

12.

Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth.

Schlecker E, Stojanovic A, Eisen C, Quack C, Falk CS, Umansky V, Cerwenka A.

J Immunol. 2012 Dec 15;189(12):5602-11. doi: 10.4049/jimmunol.1201018. Epub 2012 Nov 14.

13.

Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression.

Garcia AJ, Ruscetti M, Arenzana TL, Tran LM, Bianci-Frias D, Sybert E, Priceman SJ, Wu L, Nelson PS, Smale ST, Wu H.

Mol Cell Biol. 2014 Jun;34(11):2017-28. doi: 10.1128/MCB.00090-14. Epub 2014 Mar 24. Erratum in: Mol Cell Biol. 2014 Sep;34(17):3354.

14.

MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN.

Liu Y, Lai L, Chen Q, Song Y, Xu S, Ma F, Wang X, Wang J, Yu H, Cao X, Wang Q.

J Immunol. 2012 Jun 1;188(11):5500-10. doi: 10.4049/jimmunol.1103505. Epub 2012 Apr 27.

15.

Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.

Schouppe E, Mommer C, Movahedi K, Laoui D, Morias Y, Gysemans C, Luyckx A, De Baetselier P, Van Ginderachter JA.

Eur J Immunol. 2013 Nov;43(11):2930-42. doi: 10.1002/eji.201343349. Epub 2013 Aug 25.

17.

Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol.

Hegde VL, Nagarkatti PS, Nagarkatti M.

PLoS One. 2011 Apr 1;6(4):e18281. doi: 10.1371/journal.pone.0018281.

18.

Circulating myeloid-derived suppressor cells in patients with pancreatic cancer.

Xu XD, Hu J, Wang M, Peng F, Tian R, Guo XJ, Xie Y, Qin RY.

Hepatobiliary Pancreat Dis Int. 2016 Feb;15(1):99-105.

PMID:
26818550
19.

Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells.

Donkor MK, Lahue E, Hoke TA, Shafer LR, Coskun U, Solheim JC, Gulen D, Bishay J, Talmadge JE.

Int Immunopharmacol. 2009 Jul;9(7-8):937-48. doi: 10.1016/j.intimp.2009.03.021. Epub 2009 Apr 9.

PMID:
19362167
20.

Tumor- and organ-dependent infiltration by myeloid-derived suppressor cells.

Younos I, Donkor M, Hoke T, Dafferner A, Samson H, Westphal S, Talmadge J.

Int Immunopharmacol. 2011 Jul;11(7):816-26. doi: 10.1016/j.intimp.2011.02.021. Epub 2011 Mar 2.

PMID:
21376153

Supplemental Content

Support Center